Response to Restriction Requirement

The claims have been restricted to 46 separate groups.

Group I, is directed to Claims 1-4, 8, 12, 13, and 15-18, wherein the claims are drawn to the compounds of Formulas I and II wherein the ring is a 2-(pyridin-3-yl)-7-azabicyclo[3.3.1]non-2-ene, 3-(pyridin-3-yl)-7-azabicyclo[3.3.1]non-2-ene or a 2-(pyridin-3-yl)-7-azabicyclo[3.3.1]nonane core.

Group II is directed to Claims 1-4, 10, 12, and 14-18, wherein the claims are drawn to the compounds of Formula II wherein the ring is a 2-(pyridin-3-yl)-7-azabicyclo[3.3.1]non-2-ene, 3-(pyridin-3-yl)-7-azabicyclo[3.3.1]non-2-ene or a 2-(pyridin-3-yl)-7-azabicyclo[3.3.1]nonane core.

Group III is directed to Claims 1-3, 5, 10, and 14-17, wherein the claims are drawn to compounds of Formulas I and II, where Zj is H or j is 0, Ar is 3-pyrimidinyl, and various definitions for variables k, m, n, and p.

Group IV is directed to Claims 1-3, 10, 12, and 14-16, drawn to compounds in Formulas I and II wherein Zj is H or j is 0, Ar is 5-isoxazole, and various definitions for variables k, m, n, and p, and, further, with various definitions for the core.

Group V is directed to Claims 1-3, 6, 7, 9-12 and 14-17, drawn to compounds in Formulas I and II wherein Zj is H or j is 0, Ar is 2-(1,3,5-triazine), and various definitions for variables k, m, n, and p, and, further, with various definitions for the core.

Groups VI-X are directed to methods of treating central nervous system disorders with the compounds of Groups I-V.

Groups XI-XV are directed to methods of treating pain with the compounds of Groups I-V.

Groups XVI-XX are directed to methods of treating inflammation with the compounds of Groups I-V.

Groups XXI-XXV are directed to methods of treating cancer with the compounds of Groups I-V.

Groups XXVI-XXX are directed to methods of treating ischemia with the compounds of Groups I-V.

Groups XXXI-XXXV are directed to methods of treating drug addiction with the compounds of Groups I-V.

Groups XXXVI-XXXX are directed to methods of treating abnormal cytokine levels with the compounds of Groups I-V.

Groups XXXXI-XXXXVI are directed to compositions including the compounds of Groups I-V, and an antineoplastic agent and/or a VEGF-inhibitor, as well as a pharmaceutically acceptable carrier.

Applicants elect Group I, and wish to thank the Examiner for the helpful interview held on July 30, 2007, in which Applicants discussed the possibility of having the compositions of Group XXXXI (Claim 70) considered, as well as various method claims.

The Examiner suggested that if an election of species was made on the antineoplastic agent and/or VEGF-inhibitor in Claim 70, then the claim would be searched. Applicants select daunomycin (specifically listed in the specification) as the elected species.

The Examiner also indicated that one group of method claims would be considered upon indication of allowability of the compound claims, provided the method claims are amended to be consistent with the allowed compound claims. Applicants will amend one group of method claims upon indication of allowability of the compound claims.

In further response to the Restriction Requirement, and in an effort to facilitate prosecution, Applicants have amended the claims to cancel non-elected compound claims, and withdraw the method claims except as they would read on cancelled compound claims. Thus, Claim 1 has been amended to specify that the Ar ring is pyridine, that k and p are 1 and when m is 0, n is 1, and when m is 1, n is 0, as required by the restriction requirement. Claims 4, 11-16, and 70 are pending and un-amended. Claims 2, 3, 5-10, 20-21, 23-28, 32, 41-42, 44-49, and 53 are cancelled. Claims 17 and 18 have been amended, and Claims 35, 36, 56, and 57 have been

amended and withdrawn, to remove the non-elected cyclooctane compounds. Claims 19, 22, 29-31, 33-34, 37-40, 43, 51-52, 54-55, 58-69, and 71-72 have been withdrawn. One group of method claims will be amended in line with allowable subject matter in Group I, as indicated in the Restriction Requirement and as discussed with the Examiner in the July 30, 2007 Interview.

Applicants note that none of the Groups in the Restriction Requirement officially permits any substitution on the rings (i.e., Zj is H or j = 0). It is unclear whether this requirement is intended, as this subject matter was not mentioned in any other group. Since it is believed that it is permissible to claim compounds with some degree of substitution, Applicants have accepted the restriction to Group I, with the understanding that the rings can be substituted.

If this understanding is incorrect, then Applicants respectfully traverse on the ground that the compounds as amended have a common central core, and the MPEP states that it is not an undue burden to search compounds with a common central core. The Examiner is hereby requested to contact the undersigned attorney if this understanding is incorrect, or to search the compounds of Group I as currently claimed (i.e., including the permissible j number of Z substituents).

We also point out to the Examiner that there is at least one group missing from the list of 46 Groups in the Restriction Requirement. That is, those compounds with the 3-azabicyclo[3.2.1]oct-6-ene core are not present in any pending group. As discussed with the Examiner on July 30, 2007, he indicated that he would address this issue in the first Office Action by including an additional Group or Groups to these compounds and methods of use thereof.

It is believed that the claims as amended are fully supported by the specification, and are currently in condition for Examination on the merits. The Examiner is encouraged to contact Applicants' undersigned representative if he or she has any questions regarding the foregoing.

Respectfully submitted,

Date: 7/31/07

David S. Bradin
Registration No. 37,783

WOMBLE CARLYLE SANDRIDGE & RICE
P. O. Box 7037
Atlanta, Georgia 30357-0037
(404) 872-7000
(919) 484-2382 (direct dial)
(919) 484-2084 (facsimile)